• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Embecta Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    2/14/25 4:30:30 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email
    false 0001872789 0001872789 2025-02-12 2025-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 12, 2025

     

     

    EMBECTA CORP.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware
    (State or Other Jurisdiction of Incorporation)

     

    001-41186
    (Commission File Number)
     

    87-1583942
    (IRS Employer
    Identification No.)

     

    300 Kimball Drive, Suite 300,

    Parsippany, New Jersey
    (Address of principal executive offices)

     

      07054
    (Zip Code)

    Registrant’s telephone number, including area code: (862) 401-0000

     

    N/A
    (Former name or former address, if changed since last report)
         

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Title of each class

    Trading symbol(s)

    Name of each exchange
    on which registered

    Common Stock, par value $0.01 per share EMBC The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ¨

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

     
       

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    Embecta Corp. (“embecta”) held its Annual Meeting of Stockholders on February 12, 2025 (the “2025 Annual Meeting”). The final voting results for each of the matters submitted to a vote of stockholders at the 2025 Annual Meeting are as follows:

     

    Proposal No. 1: All of the Board of Directors’ Class III nominees for director were elected to serve for a term of one year (until the 2026 annual meeting of stockholders), by the votes set forth in the table below.

     

    Nominee For Against Abstain Broker Non-Vote
    Robert J. Hombach 48,685,580 520,342 32,024 3,705,024
    Devdatt Kurdikar 48,918,594 288,949 30,403 3,705,024
    David F. Melcher 48,231,412 972,241 34,293 3,705,024

     

     

    Proposal No. 2: The appointment of Ernst & Young LLP as embecta’s independent registered public accounting firm for fiscal year 2025 was ratified by the stockholders by the votes set forth in the table below.

    For Against Abstain Broker Non-Votes
    52,811,690 90,619 40,661 N/A

     

    Proposal No. 3: The stockholders approved, on an advisory, non-binding basis, the compensation of embecta’s named executive officers by the votes set forth in the table below.

    For Against Abstain Broker Non-Votes
    47,859,210 1,318,677 60,059 3,705,024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: February 14, 2025 EMBECTA CORP.

    By:/s/ Jeff Mann
      Jeff Mann
      

    Senior Vice President, General Counsel & Product

    Development, and Corporate Secretary

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $EMBC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • embecta to Participate in Investor Events

      PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2025 Goldman Sachs Tenth Annual Leveraged Finance and Credit Conference Management will host one-on-one investor meetings on Thursday, May 29, 2025, at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA. 2025 Jefferies Global Healthcare Conference Management will host a fireside session on Thursday, June 5, 2025, at 4:55 p.m. EDT, at the Marriott Marquis, New York City. 2025 Goldma

      5/27/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day

      PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan ("LRP"). "Our Investor Day will provide a comprehensive view of our roadmap for transitioning embecta to growth. We look forward to sharing how we are positioning embecta for long-term success in an evolving healthcare landscape," said Dev Kurdikar, President and Chief Executive Officer. "Today, we reiterate our commitment to maintaining our leadership in insulin i

      5/22/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Embecta Corp. with a new price target

      Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

      4/10/25 12:41:09 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

      12/2/24 6:56:10 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by BTIG Research with a new price target

      BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

      11/27/24 7:22:14 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

      WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

      6/20/24 7:30:00 AM ET
      $EMBC
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties